Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine-Eribulin in Cisplatin-Ineligible Advanced Urothelial Carcinoma
NCT02178241Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2014
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of eribulin in urothelial carcinoma (UC), sponsored by National Cancer Institute. Started Dec 2014; status: completed.
02
Drugs
eribulin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02178241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02178241.